Don't Buy Becton Dickinson and Company Before Checking Its Fundamentals!

By Blake Campbell • Friday, November 17 12:40 • Permanent Link

Join us for a quick overview of Becton Dickinson and Company, a Medical Instruments & Supplies company whose shares moved -0.8% today. Here are some facts about the stock that should help you see the bigger picture:

Becton Dickinson and Company has moved 4.0% over the last year, and the S&P 500 logged a change of 15.0%
BDX has an average analyst rating of buy and is -17.33% away from its mean target price of $282.0 per share
Its trailing earnings per share (EPS) is $5.1
Becton Dickinson and Company has a trailing 12 month Price to Earnings (P/E) ratio of 45.7 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $14.32 and its forward P/E ratio is 16.3
The company has a Price to Book (P/B) ratio of 2.63 in contrast to the S&P 500's average ratio of 2.95
Becton Dickinson and Company is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
BDX has reported YOY quarterly earnings growth of -60.1% and gross profit margins of 0.5%
The company has a free cash flow of $2.72 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.